859TiPTALAPRO-1: An open-label, response rate phase II study of talazoparib (TALA) in men with DNA damage repair defects (DDR) and metastatic castration-resistant prostate cancer (mCRPC) who previously received taxane-based chemotherapy (CT) and progressed on ≥ 1 novel hormonal therapy (NHT). (23rd October 2018) - de Bono, J S; Higano, C; Saad, F; Miller, K; Casey, M; Czibere, A; Healy, C; Fizazi, K